- Home
- OCS vs BHVN Comparison
OCS vs BHVN Comparison
Compare OCS & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCS | BHVN |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | OCS | BHVN |
|---|---|---|
| Price | $20.64 | $11.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $39.80 | $29.79 |
| AVG Volume (30 Days) | 97.6K | ★ 3.5M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $991,999.00 | N/A |
| Revenue This Year | $35.00 | N/A |
| Revenue Next Year | $874.12 | $2,219.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.00 | $7.48 |
| 52 Week High | $23.08 | $44.28 |
Technical Indicators
Market Signals| Indicator | OCS | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 54.90 |
| Support Level | $18.64 | $8.29 |
| Resistance Level | $21.86 | $11.71 |
| Average True Range (ATR) | 0.63 | 0.70 |
| MACD | 0.16 | 0.45 |
| Stochastic Oscillator | 62.73 | 85.91 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.